New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:06 EDTIMUCImmunoCellular granted orphan drug designation for ICT-107 by EMA
ImmunoCellular Therapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
16:29 EDTIMUCImmunoCellular appoints Dr. Swanson to lead Stem-to-T-cell research program
ImmunoCellular Therapeutics announced the appointment of Steven Swanson, PhD, as SVP, Research. Dr. Swanson will lead the company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Prior to joining ImmunoCellular, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bioanalytical procedures, immunogenicity assessment, regulatory affairs and product quality.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use